Original scientific paper

Serum Soluble OX40 in Patients with Amyotrophic Lateral Sclerosis

Joanna Iłżecka

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Data from the literature show that systemic immune activation plays a role in ALS. OX40 (CD134) is member of the tumor necrosis factor receptor family and is expressed selectively on activated T lymphocytes. The aim of the study was to measure serum soluble OX40 (sOX40) levels in patients with ALS. The study included 25 ALS patients and 15 control subjects. Serum sOX40 levels were determined by the enzyme-linked immunosorbent method. Study showed that sOX40 levels were significantly decreased in serum of ALS patients compared with controls (p=0.05). There was no significant correlation between serum sOX40 levels and clinical parameters of ALS such as severity of the ALS patient clinical state and duration of the disease (p>0.05). In conclusion, decrease in serum sOX40 levels in patients with ALS suggests that this cytokine may be implicated in the pathomechanisms of this disease.

Keywords

Amyotrophic lateral sclerosis; Neurodegeneration; Neuroprotection; Serum; Soluble OX40

Hrčak ID:

85728

URI

https://hrcak.srce.hr/85728

Publication date:

30.3.2012.

Article data in other languages: croatian

Visits: 2.131 *